The Information You Requested Could Not Be Found

Concomitant use may increase the risk for QT prolongation. Staxyn is not for use in women, and the effects of this medicine during pregnancy or in breastfeeding women are unknown. Perphenazine; Amitriptyline: Loperamide; Simethicone: Treatment with vardenafil may be initiated no sooner than 1 week after completion doses conivaptan therapy. Do not use the orally disintegrating tablets with concomitant moderate or potent CYP3A4 inhibitors e. Major Monitor electrolytes and ECGs for QT prolongation if coadministration of vardenafil staxyn oxaliplatin is necessary; correct electrolyte abnormalities prior to administration of oxaliplatin. Those patients who require a lower or higher dose of vardenafil need to be prescribed vardenafil film-coated tablets [see Patient Counseling Information 17 ]. Minor Therapeutic 10 mg and supratherapeutic 80 mg doses of vardenafil produce an increase in QTc interval e. This includes nitroglycerin, isosorbide dinitrate, and isosorbide mononitrate. Major Due to the potential for QT prolongation and torsade de pointes TdPcaution is advised when administering tolterodine with vardenafil. Major QT prolongation has occurred during therapeutic use of aripiprazole and following overdose, staxyn doses. Quinine has been associated with prolongation of the QT interval and rare cases of TdP. Vardenafil 10 mg orally disintegrating tablets provide higher systemic exposure compared to vardenfil 10 mg film-coated tablets, and these dosage forms are not doses. Limited data indicate that QT prolongation is also possible with apomorphine administration. Halogenated Staxyn How Supplied: Refer to our editorial policy for content sources and attributions. Major Concurrent use of vardenafil and levofloxacin should be avoided due to doses increased risk for QT prolongation and torsade de pointes TdP. In vitro studies have staxyn that dasatinib has the potential to prolong the QT interval.

Major Avoid coadministration of hydroxychloroquine and vardenafil. Elderly patients may potentially have renal doses hepatic impairment which can increase vardenafil plasma concentrations. Major Advise patients to avoid ingestion of grapefruit juice with vardenafil if possible. During coadministration, use vardenafil at reduced doses of no more than 2. Vardenafil is metabolized by CYP3A4. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously with vardenafil include haloperidol. QT prolongation should be expected with the administration of arsenic trioxide, staxyn doses. Use of these drugs together may increase the risk of developing torsade de pointes-type ventricular tachycardia. In addition, vardenafil is a substrate for CYP3A4. Predisposition to priapism. In addition, efavirenz induces CYP3A4 and may decrease serum concentrations of drugs metabolized by this enzyme, such as vardenafil. For patients receiving ketoconazole mg daily, the maximum single vardenafil dose is 5 mg every 24 hours. Major Avoid coadministration of vandetanib with vardenafil due to an increased risk of QT prolongation and torsade de pointes TdP. Major There may be an increased risk for QT prolongation and torsade de pointes TdP during concurrent use of mirtazapine and vardenafil. This includes prescription and over-the-counter staxyn, vitaminsand herbal products. Major Iloperidone has been associated with QT prolongation; however, torsade de pointes TdP has not been reported.

Major Although data are limited, coadministration of efavirenz and vardenafil may increase the risk for QT prolongation and torsade de pointes TdP. Drugs with a possible risk for QT prolongation and torsade de pointes that should be used cautiously and with close monitoring with panobinostat include vardenafil. Major Concomitant administration of mesoridazine with vardenafil may sstaxyn staxyn QT prolongation and should be used cautiously. It can be expected that concomitant administration of CYP3A4 enzyme-inducers, like the rifamycins, will decrease plasma levels of vardenafil. Call your doctor for stsxyn advice about side effects. By clicking Subscribe, I agree to the Drugs. Phosphodiesterase inhibitors have vasodilatory properties, and nitroprusside is a staxyn vasodilator. Major Avoid coadministration of encorafenib and vardenafil due to the potential for additive QT prolongation. Your Name Your doses is required. Doses is also a known inhibitor of the hepatic cytochrome isozyme CYP3A4. Tolterodine has been associated with dose-dependent prolongation of the QT interval, especially in poor CYP2D6 metabolizers. Fluoxetine; Olanzapine: Mitotane is a strong CYP3A4 inducer and vardenafil is a Sfaxyn substrate; coadministration may result in decreased plasma concentrations of vardenafil. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Major Droperidol should be administered with extreme caution to patients receiving other agents that may prolong the QT interval. There is no information on the presence of vardenafil and its major metabolite in human milk, the effects on the breast-fed infant, or the effects on milk production. Staxyn is not for use in women, and the effects of this medicine during pregnancy or in breastfeeding women are unknown.

Drugs with a possible risk for QT prolongation that should be used cautiously with vardenafil include fluphenazine. If these drugs must be administered together, a lower dose of vardenafil is required. Periodically monitor staxyn and ECGs; an interruption of ceritinib therapy, dose reduction, or discontinuation of therapy may be necessary if QT prolongation occurs. Inhibitors of CYP3A4, such as fluoxetine, can reduce vardenafil clearance. The safety and efficacy of combinations of vardenafil with other treatments for erectile dysfunction have not been studied. Major Due to an increased risk for QT prolongation and torsade de pointes TdPcaution is advised when administering vardenafil with gemifloxacin. Other medications which may prolong the QT interval, such as vardenafil, should be staxyn cautiously when given concurrently with lomefloxacin. Both ketoconazole and vardenafil have been associated with QT prolongation; coadministration may increase this risk. When vardenafil 10 or 20 mg was administered staxym healthy subjects taking terazosin 10 mg dailyan alphablocker, there was significant augmentation doses the hypotensive effects of terazosin on standing systolic blood pressure. If vardenafil dose adjustments are made, re-adjust the dose upon completion of boceprevir treatment. Major Because QT prolongation and torsade de pointes TdP have been reported in patients doses with fluoxetine, the manufacturer recommends caution when using fluoxetine with other drugs that prolong the QT dosess. Counseling of patients about protective measures, staxyn doses, including the prevention of transmission of human immunodeficiency virus HIV infection, should be staxtn. Limited data, including some case reports, suggest staxyn olanzapine doses be associated with a significant prolongation of the QTc interval in rare instances. Major The need to coadminister methadone with drugs known to prolong the QT interval should be done with extreme caution and a careful assessment of treatment staxyn versus benefits. An interruption of vandetanib therapy or dose reduction may be necessary for QT prolongation. Acetaminophen; Chlorpheniramine; Phenylephrine; Phenyltoloxamine: Additionally, nilotinib is a moderate CYP3A4 inhibitor and vardenafil is a CYP3A4 substrate; administering these drugs together may result in increased vardenafil levels. Erectile dysfunction. Mitotane is a strong CYP3A4 inducer and vardenafil is a CYP3A4 substrate; doses may staxyb in decreased plasma concentrations of vardenafil. Agents that prolong the QT interval could lead to torsade de pointes when combined with a phenothiazine, and therefore are generally not recommended for combined use.

Staxyn doses

Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with chloroquine include vardenafil. Otherwise, if grapefruit juice is ingested, the vardenafil dose should be reduced. About About Drugs. Major Avoid use of vardenafil during and for 2 weeks after discontinuation of itraconazole. Excessive doses particularly in the overdose setting or IV administration of haloperidol may be associated with a higher risk of QT prolongation. Patients with a sudden decrease or loss of hearing hearing impairment should stop taking vardenafil and seek prompt medical attention. Taking these drugs together increases exposure to vardenafil, and staxyn cause additive effects on the QT interval. Dozes lapatinib with extreme caution, if at all, in patients taking CYP3A4 doses that also have potential to induce QT prolongation such as vardenafil. Major The concomitant use of dabrafenib and vardenafil may lead to decreased vardenafil concentrations and loss of efficacy. Email Address. Do not take vardenafil if you are also using a doses drug for chest pain or heart problems. Therapeutic 10 mg and supratherapeutic 80 sfaxyn doses of vardenafil have also produced increases in QTc interval e. Dutasteride; Tamsulosin: Moderate Lomefloxacin has been associated with Staxyn prolongation and infrequent cases of arrhythmia. Severe Coadministration of riociguat and vardenafil is contraindicated due to the risk of hypotension. If used together, the vardenafil dose should not exceed 2.

If concomitant use of these agents together is unavoidable, monitor patients for loss of vardenafil efficacy. Aripiprazole should be used cautiously and with close monitoring with vardenafil. This doses is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Additionally, nilotinib is a moderate CYP3A4 inhibitor and vardenafil is a CYP3A4 substrate; administering these drugs together may result xoses increased vardenafil levels. Dronedarone administration is associated with a dose-related increase in the QTc interval. Dextromethorphan; Staxyn For patients receiving ketoconazole mg daily, the maximum single vardenafil dose is 2. Major Due to the potential for QT interval prolongation with primaquine, caution is advised with other drugs that prolong the QT interval. The manufacturer of tadalafil recommends to avoid the use of tadalafil with any other PDE5 inhibitors, staxyn doses. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and dosew close monitoring with triptorelin include vardenafil. Prolonged erections greater staxynn 4 hours and priapism painful erections greater than 6 hours in duration have been associated with PDE5 inhibitor administration. Concomitant Medications Nitrates: After staxyn, fosaprepitant is rapidly converted to aprepitant and shares ddoses of the same drug interactions. Odses treatment options include intracavernous injection and intra-urethral therapy. If these drugs are used together, closely monitor for signs of adverse events. This risk is generally higher at elevated drugs concentrations of phenothiazines. The stxayn decrease in blood pressure occurred between 1 and 4 hours after doses. An erection will not occur just by taking a pill. Carbetapentane; Phenylephrine: Staxyn is taken only when needed, about 60 minutes before sexual activity. It should be taken immediately upon removal from the blister. According to the manufacturer, since iloperidone may prolong the QT interval, it should be avoided in combination with other agents also known to have this effect, such as vardenafil. FDA alerts for all medications. If coadministered, use vardenafil at reduced doses dosds 2. Vardenafil is administered orally.

Vardenafil orally disintegrating tablets provide increased exposure as compared to the regular tablets; therefore, use with moderate or potent CYP3A4 inhibitors is not recommended. Isoniazid, INH; Rifampin: Severe Concurrent use of fluconazole and vardenafil is contraindicated due to the risk of life threatening arrhythmias such as torsade de pointes TdP. Major Although data are limited, coadministration of efavirenz and vardenafil may increase the risk for QT prolongation and torsade de pointes TdP. Since bradycardia is a risk factor for development of TdP, the potential occurrence of bradycardia during octreotide administration could theoretically increase the risk of TdP in patients receiving drugs that prolong the QT interval. Additionally, fluconazole staxyn been associated with prolongation of the QT interval; do not use with other drugs that may prolong the QT interval and are metabolized through CYP3A4, such as vardenafil. Additionally, rare cases of TdP have been spontaneously reported during postmarketing surveillance in patients receiving levofloxacin. Caution is advisable during concurrent use of other agents associated with a possible risk for QT prolongation and TdP including vardenafil. Doses increases the QT interval and should not be administered with other drugs known to prolong the QT interval. Lesinurad; Allopurinol: Major Coadministration of vardenafil with fosamprenavir, especially when 'boosted' with ritonavir, is expected to substantially increase vardenafil plasma concentrations and may result in increased associated adverse events including hypotension, syncope, visual changes, and prolonged erection. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously with arsenic trioxide include vardenafil. Patients should be stabilized on their alpha blocker therapy prior to starting either avanafil, tadalafil or vardenafil, staxyn doses, or if already receiving an optimum dose of these PDE5 inhibitors, the alpha blocker therapy should be started at the staxyn possible dose. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. If these drugs are used together, monitor patients for suboptimal efficacy of vardenafil; consider increasing the dose of vardenafil if necessary. The maximum decrease in blood pressure occurred between 1 and 4 hours after dosing. Major Concurrent use of quinine and vardenafil should be avoided due to an increased risk for QT prolongation and torsade de pointes TdP. If lapatinib will be coadministered with a CYP3A4 substrate, exercise caution and consider dose reduction of the concomitant doses drug, especially for drugs that have a narrow therapeutic index. Health care professionals should consider whether the individual would be adversely affected by vasodilatory events. Drugs that are CYP3A4 substrates that also have a possible risk for QT prolongation and TdP that should be used cautiously with ranolazine include vardenafil. There is a degree of cardiac risk associated with sexual activity; therefore, prescribers should evaluate the cardiovascular status of their patients prior to initiating any treatment for erectile dysfunction.

Drugs with a dosex risk for QT prolongation and TdP that should be used cautiously with vardenafil include venlafaxine. According to staxyn manufacturer of asenapine, the drug should be avoided doses combination with other agents also known to have this effect, such as vardenafil. Vardenafil is administered orally. Although it staxyn best to avoid this drug combination if possible, if no acceptable alternative therapy is available, perform a baseline ECG prior to initiation of concomitant therapy see Contraindicationsand use vardenafil at reduced doses of no more than 2. About Staxyn Drugs. Elbasvir; Grazoprevir: Major Avoid coadministration of ribociclib with vardenafil due to an increased risk for QT prolongation and dkses de pointes TdP. Major Concurrent use of vardenafil and artemether; lumefantrine should be avoided due to an increased risk for QT prolongation and torsade de pointes TdP. Major Due to increased vardenafil exposure, staxyn doses, do not use vardenafil orally staxyn tablets with letermovir; do not doses a single dose of 5 mg per hour period of vardenafil oral tablets. As a single mg or 40 mg oral dose, the inhibitory effect of aprepitant on CYP3A4 is weak, with the AUC of midazolam increased by 1. Major When possible, avoid concurrent use of foscarnet doses other drugs known to prolong the QT interval, such as vardenafil. If these agents are used together, obtain an ECG and serum electrolytes prior to the start of gemtuzumab and as needed during treatment. Granisetron has been associated with QT prolongation. An additive effect doees blood pressure is anticipated. Patients refractory to PDE5 inhibitors should doses counseled on appropriate use, potentially modifiable factors e.

More about Staxyn (vardenafil)

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as vardenafil. Drugs with a possible risk for QT prolongation and torsade de pointes TdP that should be used cautiously and with close monitoring with eliglustat include vardenafil. If you receive medical care for heart problems, tell your caregivers when you last took vardenafil. Major There have been postmarketing reports of QT prolongation and torsade de pointes TdP during treatment with sertraline and the manufacturer of sertraline recommends avoiding concurrent use with drugs known to prolong the QTc interval. If these drugs are used together, closely monitor for signs of adverse events. Major Monitor electrolytes and ECGs for QT prolongation if coadministration of vardenafil with oxaliplatin is necessary; correct electrolyte abnormalities prior to administration of oxaliplatin. Mitotane is a strong CYP3A4 inducer and vardenafil is a CYP3A4 substrate; coadministration may result in decreased plasma concentrations of vardenafil. Other potent CYP3A4 inhibitors such as, imatinib, STI, would be expected to have effects on vardenafil clearance when coadministered. Use of these drugs together may increase the risk of developing torsade de pointes-type ventricular tachycardia. Vardenafil is a substrate of the hepatic isoenzyme CYP3A4; telaprevir inhibits this isoenzyme. Coadministration of lopinavir; ritonavir with other drugs that prolong the QT interval, such as vardenafil, may result in additive QT prolongation. Do not use vardenafil orally disintegrating tablets in patients with moderate hepatic impairment. Treatment with vardenafil may be initiated no sooner than 1 week after completion of conivaptan therapy. Tamoxifen has been reported to prolong the QT interval, usually in overdose or when used in high doses. Major Chloroquine administration is associated with an increased risk of QT prolongation and torsades de pointes TdP. Major Particular caution should be used when prescribing vardenafil to patients receiving atazanavir. Avoid medication errors by using only the form and strength your doctor prescribes. Major Due to a possible risk for QT prolongation and torsade de pointes TdP , ondansetron and vardenafil should be used together cautiously. Major If used together, the vardenafil tablet dose should not exceed 2.

Reports of QT prolongation and TdP during risperidone therapy have occurred primarily in the setting of overdose. Vardenafil has a greater selectivity for PDE5 versus PDE6, an enzyme found in the retina and involved in phototransduction. Major Avoid use of vardenafil during and for 2 weeks after discontinuation of itraconazole. The elimination half-life of vardenafil and M1 is about 4—5 hours with the use of the film-coated tablets. A course of an alternate PDE5 inhibitor may be considered if a patient does not respond to a PDE5 inhibitor trial; a treatment failure may be deemed after at least 4 unsuccessful trials. Both therapeutic and supratherapeutic doses of vardenafil produce an increase in QTc interval e. Although QT interval prolongation has not been reported with gemtuzumab, it has been reported with other drugs that contain calicheamicin. Vardenafil, at therapeutic 10 mg and supratherapeutic 80 mg doses, produces an increase in QTc interval e. Tamoxifen has been reported to prolong the QT interval, usually in overdose or when used in high doses. In healthy volunteers, peak plasma concentrations Cmax following a single 20 mg oral tablet dose are usually reached between 30 minutes and 2 hours median 60 minutes in the fasted state. Posaconazole is a potent inhibitor of CYP3A4, an isoenzyme responsible for the metabolism of vardenafil. Drugs with a possible risk for QT prolongation and torsade de pointes TdP that should be used cautiously and with close monitoring with eliglustat include vardenafil. The manufacturer recommends that vardenafil not be used in patients with congenital long QT syndrome and those taking Class IA e. It can be expected that concomitant administration of CYP3A4 enzyme-inducers, such as carbamazepine, will decrease plasma levels of vardenafil, however, no interaction studies have been performed. Major Ranolazine is associated with dose- and plasma concentration-related increases in the QTc interval. After administration, fosaprepitant is rapidly converted to aprepitant and shares many of the same drug interactions. Related Drugs. Proarrhythmic events should be anticipated after initiation of therapy and after each upward dosage adjustment. Predictions about the interaction can be made based on the metabolic pathways of vardenafil. Other brands: A course of an alternate PDE5 inhibitor may be considered if a staxyn does not respond to a PDE5 inhibitor trial; a treatment failure may be deemed after at least 4 unsuccessful trials. For patients receiving ketoconazole mg ztaxyn, the maximum single vardenafil dose is 2. Vardenafil dose adjustments are required when vardenafil is administered with such agents, staxyn doses. Coadministration of atazanavir with vardenafil is expected to substantially increase vardenafil plasma concentrations and may result in increased associated adverse events including hypotension, syncope, visual changes, and prolonged erection. The dises recommends that vardenafil not be used in doses with congenital long QT syndrome and those taking Dosez IA e.

Sunitinib can cause dose-dependent QT prolongation, which may increase the risk for ventricular arrhythmias, including torsades de points TdP. Do not use. Concomitant use may increase the risk for QT prolongation. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with anagrelide include vardenafil. Major Due to the potential for QT prolongation and torsade de pointes TdP , caution is advised when administering tolterodine with vardenafil. Major The safety and efficacy of tadalafil administered concurrently with any other phosphodiesterase PDE5 inhibitors, such as vardenafil, has not been studied. Use in Special Populations Hepatic Impairment: Monthly newsletter. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously with vardenafil include ezogabine. For patients receiving ketoconazole mg daily, the maximum single vardenafil dose is 2. Excessive doses particularly in the overdose setting or IV administration of haloperidol may be associated with a higher risk of QT prolongation. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously with vardenafil include perphenazine. An interruption of therapy, dose reduction, or discontinuation of therapy may be necessary for crizotinib patients if QT prolongation occurs. Both ketoconazole and vardenafil have been associated with QT prolongation; coadministration may increase this risk. Major There may be an increased risk for QT prolongation, torsade de pointes TdP , or increased vardenafil concentrations during concurrent use of fluvoxamine and vardenafil. In clinical trials, QT prolongation has been reported in patients who received midostaurin as single-agent therapy or in combination with cytarabine and daunorubicin. Encorafenib is associated with dose-dependent prolongation of the QT interval. Use Staxyn orally disintegrating tablets exactly as prescribed by your doctor. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with primaquine include vardenafil. Vardenafil orally disintegrating tablets ODT provide increased exposure as compared to the regular tablets; therefore, use with potent CYP3A4 inhibitors such as delavirdine is not recommended. Dyspepsia is one of the more common adverse reactions associated with PDE inhibitor therapy. Moderate Lesinurad may decrease the systemic exposure and therapeutic efficacy of vardenafil; monitor for potential reduction in efficacy. Drug Interactions in more detail. Patients refractory to PDE5 inhibitors should be counseled on appropriate use, potentially modifiable factors e. Coadministration of indinavir mg every 8 hours with a single dose of vardenafil 10 mg altered the pharmacokinetics of vardenafil with a fold increase in AUC, a 7-fold increase in Cmax, and a 2-fold increase in half-life. Major Due to a doses risk for QT prolongation and torsade de pointes TdPondansetron and vardenafil should be used together cautiously. Increased systemic exposure to vardenafil may result in an increase in vardenafil-induced adverse effects. Androgen deprivation dosss e. Use vardenafil at reduced doses of no more than 2. Adult males taking erythromycin, ketoconazole mg staxyn, or itraconazole mg daily. Concurrent use of PDE5 inhibitors and alpha-blockers may lead to symptomatic hypotension dosees some patients. Patients with known risk factors for cardiac disease or arrhythmias should be closely monitored. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously with vardenafil include degarelix. ECG monitoring is recommended; closely monitor the patient for QT interval prolongation.